Wednesday, May 21, 2025
  • Advertise
  • Recruitment
  • Contact us:
  • Register
Irish Pharmacy News
  • News
    • Latest
    • Community Pharmacy
  • Learning
    • CPD
    • Features
    • Team Training
    • Research
  • Magazines
  • OTC
    • OTC Awards
    • Product News
  • Awards
    • Irish Pharmacy Awards 2024
    • Awards News
  • HPN
  • Log In
  • Register
No Result
View All Result
  • News
    • Latest
    • Community Pharmacy
  • Learning
    • CPD
    • Features
    • Team Training
    • Research
  • Magazines
  • OTC
    • OTC Awards
    • Product News
  • Awards
    • Irish Pharmacy Awards 2024
    • Awards News
  • HPN
  • Log In
  • Register
No Result
View All Result
Irish Pharmacy News
Home Developments

Drug could potentially prevent respiratory and cardiovascular damage in Covid-19 patients

Robyn Maginnis by Robyn Maginnis
14 July 2021
in Developments
0
Drug could potentially prevent respiratory and cardiovascular damage in Covid-19 patients

A mutation in all SARS-CoV-2 variants results in significant damage to the lung tissue and blood vessels, RCSI research

Scientists have identified a drug that can prevent the virus that causes COVID-19 from binding to human cells, potentially preventing damage to the lung, clot formation and the development of sepsis.

The study, led by researchers from RCSI University of Medicine and Health Sciences, is published in PLOS ONE.

The researchers identified that a mutation, present in all the variants of the virus to date, creates an additional binding site in the virus’ spike protein. This additional binding site increases viral impact in the body, including damage to the lung tissue that causes breathing problems in COVID-19 patients.

The significant damage to the lung tissue allows the virus to spread from the lungs to the bloodstream, where it can cause clots and vascular damage.

In pre-clinical testing, a drug called cilengitide successfully prevented the virus from causing the tissue damage associated with COVID-19 by stopping the virus from sticking to the cell types that line the lungs and blood vessels.

“More pre-clinical and clinical testing is needed before this treatment can be used on patients, but the results are very promising,” said Professor Steve Kerrigan, the study’s senior author and Deputy Head of the RCSI School of Pharmacy and Biomolecular Sciences.

“It is imperative that we continue to develop treatments for COVID-19 for the many people who will not have access to vaccines and for patients with breakthrough infections. Our research in the lab has shown that cilengitide has the potential to significantly reduce the deaths associated with COVID-19.”

RCSI spin-out company Inthelia Therapeutics has recently been formed to commercialise this and other findings relating to the treatment of sepsis from Professor Kerrigan’s research group.

Ms Danielle Nader, PhD candidate in Professor Kerrigan’s group, carried out the work. The research was funded by an Enterprise Ireland Commercialisation Fund, an EMBARK fund award from Enterprise Ireland and Knowledge Transfer Ireland as well as a philanthropic donation from the 3M Foundation and GlobalGiving.

Previous Post

CPD: Bladder Problems in Men – You are Not Alone

Next Post

Age-Related Macular Degeneration

Next Post
Age-Related Macular Degeneration

Age-Related Macular Degeneration

Leave a Reply

Your email address will not be published. Required fields are marked *

More Than Skin Deep: The Rise of Hair and Nail Wellness

More Than Skin Deep: The Rise of Hair and Nail Wellness

21 May 2025
wins

ALFLOREX® WINS AT IRISH PHARMACY NEWS OTC AWARDS FOR NINTH YEAR IN A ROW

20 May 2025
Blackberry hearing secures Uniphar deal

Blackberry hearing secures Uniphar deal

15 May 2025

RECOMMENDED NEWS

Opportunity for Pharmacy to Empower Women

Opportunity for Pharmacy to Empower Women

4 years ago

Keane’s CarePlus Pharmacies become the First Pharmacies in Ireland to Be Accredited as Autism Friendly by AsIAm

6 years ago
Best Baby Skincare Product – Elave Sensitive Baby Bath

Best Baby Skincare Product – Elave Sensitive Baby Bath

2 years ago

Neocate LCP – Change in Case Size & new EU Regulations

5 years ago
Tweets by Irish_PharmNews

Quick links

  • About
  • Advertise
  • Careers
  • Contact us

Follow us on social media:

Other info

  • Contact us
  • Register for Digital Magazines
  • Privacy Policy
  • About
  • Advertise
  • Careers
  • Contact us

© 2024 IPN

No Result
View All Result
  • News
  • Learning
  • Other
    • Conferencing
    • Developments
    • Product News
    • Profiles
    • Research
  • Digital Magazines (IPN Online Issues Older Issue Tabs)
  • Awards

© 2024 IPN

  • Login

    Forgot password? | Register

    Register

    Registration confirmation will be emailed to you.

    Login | Forgot password?

    Reset Password

    Please enter your username or email address. You will receive a link to create a new password via email.

    Login

Login

Register

Forgotten Password?

Register | Lost your password?
| Back to Login